DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more
DNA Link Inc (127120) - Total Assets
Latest total assets as of September 2025: ₩94.71 Billion KRW
Based on the latest financial reports, DNA Link Inc (127120) holds total assets worth ₩94.71 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DNA Link Inc - Total Assets Trend (2011–2024)
This chart illustrates how DNA Link Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
DNA Link Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
DNA Link Inc's total assets of ₩94.71 Billion consist of 26.3% current assets and 73.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩4.62 Billion | 0.2% |
| Accounts Receivable | ₩3.05 Billion | 5.6% |
| Inventory | ₩2.59 Billion | 4.8% |
| Property, Plant & Equipment | ₩24.17 Billion | 44.5% |
| Intangible Assets | ₩183.76 Million | 0.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how DNA Link Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DNA Link Inc's current assets represent 26.3% of total assets in 2024, a decrease from 53.8% in 2011.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2024, down from 16.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 44.5% of total assets.
DNA Link Inc Competitors by Total Assets
Key competitors of DNA Link Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
DNA Link Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - DNA Link Inc generates 0.29x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - DNA Link Inc is currently not profitable relative to its asset base.
DNA Link Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 1.14 | 3.25 |
| Quick Ratio | 0.49 | 0.96 | 2.99 |
| Cash Ratio | 0.00 | 0.46 | 0.00 |
| Working Capital | ₩-19.45 Billion | ₩ 2.92 Billion | ₩ 32.82 Billion |
DNA Link Inc - Advanced Valuation Insights
This section examines the relationship between DNA Link Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 18.77 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 40.3% |
| Total Assets | ₩54.39 Billion |
| Market Capitalization | $538.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values DNA Link Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: DNA Link Inc's assets grew by 40.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for DNA Link Inc (2011–2024)
The table below shows the annual total assets of DNA Link Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩54.39 Billion | +40.32% |
| 2023-12-31 | ₩38.76 Billion | -10.92% |
| 2022-12-31 | ₩43.51 Billion | +6.07% |
| 2021-12-31 | ₩41.02 Billion | -21.94% |
| 2020-12-31 | ₩52.54 Billion | +102.87% |
| 2019-12-31 | ₩25.90 Billion | -26.14% |
| 2018-12-31 | ₩35.07 Billion | +39.89% |
| 2017-12-31 | ₩25.07 Billion | -3.07% |
| 2016-12-31 | ₩25.86 Billion | -20.99% |
| 2015-12-31 | ₩32.73 Billion | +59.84% |
| 2014-12-31 | ₩20.48 Billion | -31.82% |
| 2012-12-31 | ₩30.03 Billion | +46.56% |
| 2011-12-31 | ₩20.49 Billion | -- |